Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Durvalumab and Standard Chemotherapy for the Treatment of Lymph Node Positive Bladder Cancer

NCT05137262 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT05137262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05137262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Durvalumab and Standard Chemotherapy for the Treatment of Lymph Node Positive Bladder Cancer
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 13, 2021
Completion date
August 31, 2028
Enrollment
12 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, urothelial carcinoma